The Second Sight Medical Products Inc. (EYES) Rating Reiterate by HC Wainwright

The Second Sight Medical Products Inc. (EYES) Rating Reiterate by HC Wainwright

Second Sight Medical Products Inc. (NASDAQ:EYES)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Thursday. They presently have a $16.00 target price on the medical device company’s stock. HC Wainwright’s target price points to a potential upside of 481.82% from the company’s previous close.

Separately, Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price objective on shares of Second Sight Medical Products in a research report on Tuesday, July 26th.

Shares of Second Sight Medical Products (NASDAQ:EYES) opened at 2.75 on Thursday. The company has a 50-day moving average price of $3.17 and a 200-day moving average price of $3.82. The stock’s market cap is $116.05 million. Second Sight Medical Products has a 52 week low of $2.56 and a 52 week high of $7.87.

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Second Sight Medical Products by 0.8% in the first quarter. Geode Capital Management LLC now owns 95,394 shares of the medical device company’s stock valued at $460,000 after buying an additional 772 shares during the last quarter. Harvest Capital Strategies LLC boosted its position in shares of Second Sight Medical Products by 759.1% in the first quarter. Harvest Capital Strategies LLC now owns 382,281 shares of the medical device company’s stock valued at $1,846,000 after buying an additional 337,783 shares during the last quarter. Carl Domino Inc boosted its position in shares of Second Sight Medical Products by 44.8% in the second quarter. Carl Domino Inc now owns 43,435 shares of the medical device company’s stock valued at $155,000 after buying an additional 13,435 shares during the last quarter. Van Den Berg Management I Inc. boosted its position in shares of Second Sight Medical Products by 1,129.6% in the second quarter. Van Den Berg Management I Inc. now owns 167,220 shares of the medical device company’s stock valued at $599,000 after buying an additional 153,620 shares during the last quarter. Finally, Psagot Investment House Ltd. boosted its position in shares of Second Sight Medical Products by 16.6% in the second quarter. Psagot Investment House Ltd. now owns 55,362 shares of the medical device company’s stock valued at $198,000 after buying an additional 7,878 shares during the last quarter. 6.85% of the stock is currently owned by institutional investors and hedge funds.

About Second Sight Medical Products

Related posts

Leave a Comment